Transcatheter pulmonary valve replacement

Last updated

Transcatheter pulmonary valve replacement
Other namesTPVR, percutaneous pulmonary valve implantation (PPVI)
Specialty Interventional cardiology
Uses Congenital defects of the right ventricular outflow tract, failing artificial valves
ComplicationsStent fracture, infective endocarditis
Other optionsOpen heart surgery
Outcomes92%-98% successful implantation [1]

Transcatheter pulmonary valve replacement (TPVR), also known as percutaneous pulmonary valve implantation (PPVI), is the replacement of the pulmonary valve via catheterization through a vein. It is a significantly less invasive procedure in comparison to open heart surgery and is commonly used to treat conditions such as pulmonary atresia. [2] [3]

Contents

Uses

TPVR can be used to repair congenital defects in the pulmonary valve or right ventricular outflow tract dysfunction, such as pulmonary atresia, Tetralogy of Fallot, or persistent truncus arteriosus. [4] TPVR can also be used to replace dysfunctional artificial heart valves. [1]

For those experiencing symptoms, TPVR is indicated when the right ventricular systolic pressure is above 60 mmHg and/or when there is moderate to severe pulmonary regurgitation. [4] For those not experiencing any symptoms, TPVR is indicated if there is severe right ventricular outflow tract narrowing and/or severe pulmonary insufficiency, with decreased exercise capacity, progressive right ventricular dilation, progressive right ventricular dysfunction, progressive tricuspid valve regurgitation, right ventricular systolic pressure above 80 mmHg, or cardiac fibrillation. [4]

For dysfunctional artificial conduits, TPVR immediately resolves pulmonary regurgitation and normalizes the right ventricular outflow tract gradient, and is associated with significant improvements in symptoms and improvements in long-term ventricular function. [1]

Contraindications

Active infection, central vein occlusion, coronary occlusion, and need for other surgeries such as for arrhythmia are contraindications for TPVR. [4] [1]

If coronary compression (which impairs coronary blood flow) is observed with balloon dilation in the right ventricular outflow tract, TPVR is also contraindicated. [4] This test is performed to prevent potentially fatal complications, for which approximately 5% of candidates are at risk. [4]

TPVR is not recommended for tracts that are less than 16 mm [4] or more than 29 mm in diameter. [1]

Complications

There is a low incidence of major complications, which is likely due to pre-procedural assessments preventing individuals with unfavourable anatomy from undergoing the procedure. [5]

The most common complication is fracture of the stent frame. [4] This is seen in up to 30% of cases. [4] The majority of stent fractures are diagnosed by routine imaging and are not clinically relevant. [4] Stent fractures leading to obstruction of the right ventricular outflow tract is the most common reason for repeat intervention and can be treated with valve-in-valve procedures (placing a new valve inside the failed valve). [4] More severe fractures may require surgery. [4] Risk factors for stent fractures include younger age, smaller tract diameter, and position of the valve directly below the sternum. [4]

Tears or ruptures of the right ventricular outflow tract may occur during the procedure, especially if the tract is already heavily calcified. [4] This is reported to occur in up to 9% of procedures. [4] Most cases are manageable by using a covered stent and do not lead to severe bleeding. [4]

Infective endocarditis occurs at a rate of about 1%-3%. [1] Most cases do not directly impact the implanted valve, and most cases can be treated with antibiotics. [4] However, infective endocarditis can also cause valve explantation or sepsis, which can lead to death. [4]

Rare complications that may require urgent surgery include valve migration, valve embolization, pulmonary artery occlusion, pulmonary artery rupture, or coronary artery compression impeding blood flow. [4] [5]

Death is rare, and is usually attributable to other comorbidities rather than from the implantation procedure itself. [4]

Procedure

Pre-procedural assessment

Several tests are performed before the procedure to assess whether the procedure is suitable for the individual and to record their anatomy in preparation for the procedure. [4] [6] Ventricular function and size are assessed with an echocardiogram. [4] The right ventricle and the anatomy of the outflow tract, including any anatomical variations, are also assessed with cardiac magnetic resonance imaging. [4] [6] The severity of the outflow tract defect or pulmonary regurgitation is assessed with Doppler ultrasonography. [4]

Operation

TPVR is a percutaneous procedure, meaning the device is brought into the body through the skin and into a vein. Patients are put under general anesthesia. [4] The heart is typically reached by passing through the femoral vein, jugular vein, or subclavian vein. [4] A balloon dilation test is performed first, to confirm that coronary compression will not occur and the procedure can continue. [4] [6] Stent fractures can be prevented by using pre-stenting, using a bare metal stent before TPVR. [5] After the valve is implanted, balloon dilation is used to create the diameter of the valve. [6] At the end of the procedure, pressure is applied to the area to encourage hemostasis (stop bleeding). [6]

Recovery

Patients undergoing TPVR are typically ambulatory within 6 hours of finishing the procedure and can be discharged home within 24 hours. [6] As cardiopulmonary bypass is not required, a stay in the intensive care unit and an extended hospital stay are generally not needed. [6]

History

TPVR was developed as a less invasive alternative to other treatment options requiring open heart surgery, such as patch augmentation, replacing the native valve with an artificial heart valve, or using a valved conduit. [4] These surgeries typically require repeat surgeries to repair issues including pulmonary regurgitation, valve narrowing, kinking of the conduit, or calcification, leading to significant morbidity. [4]

The first TPVR was performed in 2000. [4] [7] This device was further developed into the Melody transcatheter pulmonary valve by Medtronic. [4] [6] The Melody device received approval from Health Canada in 2006 and from the US Food and Drug Administration (FDA) in 2010. [6] A similar device, the Edwards Sapien pulmonic transcatheter heart valve, produced by Edwards Lifesciences, first received FDA approval in 2015. [4] [8]

The comparatively lower risks of TPVR and reduced need for reintervention compared to traditional surgical treatments has led to a paradigm shift favouring earlier treatment for right ventricular outflow tract defects, which were previously postponed due to the risks of traditional surgery. [1] [9]

See also

Related Research Articles

<span class="mw-page-title-main">Cardiology</span> Branch of medicine dealing with the heart

Cardiology is the study of the heart. Cardiology is a branch of medicine that deals with disorders of the heart and the cardiovascular system. The field includes medical diagnosis and treatment of congenital heart defects, coronary artery disease, heart failure, valvular heart disease, and electrophysiology. Physicians who specialize in this field of medicine are called cardiologists, a specialty of internal medicine. Pediatric cardiologists are pediatricians who specialize in cardiology. Physicians who specialize in cardiac surgery are called cardiothoracic surgeons or cardiac surgeons, a specialty of general surgery.

<span class="mw-page-title-main">Angioplasty</span> Procedure to widen narrow arteries or veins

Angioplasty, also known as balloon angioplasty and percutaneous transluminal angioplasty (PTA), is a minimally invasive endovascular procedure used to widen narrowed or obstructed arteries or veins, typically to treat arterial atherosclerosis. A deflated balloon attached to a catheter is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. A stent may be inserted at the time of ballooning to ensure the vessel remains open, and the balloon is then deflated and withdrawn. Angioplasty has come to include all manner of vascular interventions that are typically performed percutaneously.

<span class="mw-page-title-main">Aortic stenosis</span> Narrowing of the exit of the hearts left ventricle

Aortic stenosis is the narrowing of the exit of the left ventricle of the heart, such that problems result. It may occur at the aortic valve as well as above and below this level. It typically gets worse over time. Symptoms often come on gradually with a decreased ability to exercise often occurring first. If heart failure, loss of consciousness, or heart related chest pain occur due to AS the outcomes are worse. Loss of consciousness typically occurs with standing or exercising. Signs of heart failure include shortness of breath especially when lying down, at night, or with exercise, and swelling of the legs. Thickening of the valve without narrowing is known as aortic sclerosis.

<span class="mw-page-title-main">Aortic valve</span> Valve in the human heart between the left ventricle and the aorta

The aortic valve is a valve in the heart of humans and most other animals, located between the left ventricle and the aorta. It is one of the four valves of the heart and one of the two semilunar valves, the other being the pulmonary valve. The aortic valve normally has three cusps or leaflets, although in 1–2% of the population it is found to congenitally have two leaflets. The aortic valve is the last structure in the heart the blood travels through before stopping the flow through the systemic circulation.

<span class="mw-page-title-main">Tetralogy of Fallot</span> Type of congenital heart defect

Tetralogy of Fallot (TOF), formerly known as Steno-Fallot tetralogy, is a congenital heart defect characterized by four specific cardiac defects. Classically, the four defects are:

<span class="mw-page-title-main">Interventional cardiology</span>

Interventional cardiology is a branch of cardiology that deals specifically with the catheter based treatment of structural heart diseases. Andreas Gruentzig is considered the father of interventional cardiology after the development of angioplasty by interventional radiologist Charles Dotter.

<span class="mw-page-title-main">Mitral regurgitation</span> Form of valvular heart disease

Mitral regurgitation(MR), also known as mitral insufficiency or mitral incompetence, is a form of valvular heart disease in which the mitral valve is insufficient and does not close properly when the heart pumps out blood. It is the abnormal leaking of blood backwards – regurgitation from the left ventricle, through the mitral valve, into the left atrium, when the left ventricle contracts. Mitral regurgitation is the most common form of valvular heart disease.

Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve. The aortic valve may need to be replaced because:

<span class="mw-page-title-main">Cardiac catheterization</span> Insertion of a catheter into a chamber or vessel of the heart

Cardiac catheterization is the insertion of a catheter into a chamber or vessel of the heart. This is done both for diagnostic and interventional purposes.

The Rastelli procedure is an open heart surgical procedure developed by Italian physician and cardiac surgery researcher, Giancarlo Rastelli, in 1967 at the Mayo Clinic, and involves using a pulmonary or aortic homograft conduit to relieve pulmonary obstruction in double outlet right ventricle with pulmonary stenosis.

<span class="mw-page-title-main">Arterial switch operation</span> Open heart surgical procedure

Arterial switch operation (ASO) or arterial switch, is an open heart surgical procedure used to correct dextro-transposition of the great arteries (d-TGA).

<span class="mw-page-title-main">Drug-eluting stent</span> Medical stent that releases drug

A drug-eluting stent (DES) is a thin tube that is used to treat narrowed arteries in medical procedures. It releases drugs to prevent the growth of scar tissue and reduce the risk of stent restenosis, which is the narrowing of the stented area of an artery after treatment. A drug-eluting stent is different from other types of stents because it has a coating that delivers medication directly to the arterial wall. A DES is often made of metal alloys and can be inserted into blocked or narrowed arteries through a catheter placed in a peripheral artery, such as in the arm or leg. DES is fully integrated with a catheter delivery system and is viewed as one integrated medical device.

<span class="mw-page-title-main">Transcatheter aortic valve replacement</span> Technique for replacement of the aortic valve in a heart

Transcatheter aortic valve replacement (TAVR) is the replacement of the aortic valve of the heart through the blood vessels. The replacement valve is delivered via one of several access methods: transfemoral, transapical, subclavian, direct aortic, and transcaval, among others.

<span class="mw-page-title-main">Ross procedure</span> Type of cardiac surgical operation

The Ross procedure, also known as pulmonary autograft, is a heart valve replacement operation to treat severe aortic valve disease, such as in children and young adults with a bicuspid aortic valve. It involves removing the diseased aortic valve, situated at the exit of the left side of the heart, and replacing it with the person's own healthy pulmonary valve (autograft), removed from the exit of the heart's right side. To reconstruct the right sided exit, a pulmonary valve from a cadaver (homograft), or a stentless xenograft, is used to replace the removed pulmonary valve. Compared to a mechanical valve replacement, it avoids the requirement for thinning the blood, has favourable blood flow dynamics, allows growth of the valve with growth of the child and has less risk of endocarditis.

The following outline is provided as an overview of and topical guide to cardiology, the branch of medicine dealing with disorders of the human heart. The field includes medical diagnosis and treatment of congenital heart defects, coronary artery disease, heart failure, valvular heart disease and electrophysiology. Physicians who specialize in cardiology are called cardiologists.

Impella is a family of medical devices used for temporary ventricular support in patients with depressed heart function. Some versions of the device can provide left heart support during other forms of mechanical circulatory support including ECMO and Centrimag.

<span class="mw-page-title-main">Hybrid cardiac surgery</span>

A hybrid cardiac surgical procedure in a narrow sense is defined as a procedure that combines a conventional, more invasive surgical part with an interventional part, using some sort of catheter-based procedure guided by fluoroscopy imaging in a hybrid operating room (OR) without interruption. The hybrid technique has a reduced risk of surgical complications and has shown decreased recovery time. It can be used to treat numerous heart diseases and conditions and with the increasing complexity of each case, the hybrid surgical technique is becoming more common.

Barry A. Love is an American cardiologist specializing in pediatric and congenital heart problems.

The LeCompte maneuver is a technique used in open heart surgery, primarily on infants and children. The maneuver entails cutting the main pulmonary artery and moving it anterior to the aorta before reattaching the pulmonary artery during the following reconstruction of the great vessels. It allows the surgeon to reconstruct the right ventricular outflow tract without needing to connect the proximal and distal sections with a graft. It also enables the surgeon to avoid compressing the coronary arteries and relieves compression of the bronchi in cases where the pulmonary artery is severely dilated or aneurysmal. If both pulmonary arteries are not mobilized adequately, they can become stretched, leading to pulmonic stenosis.

The Yasui procedure is a pediatric heart operation used to bypass the left ventricular outflow tract (LVOT) that combines the aortic repair of the Norwood procedure and a shunt similar to that used in the Rastelli procedure in a single operation. It is used to repair defects that result in the physiology of hypoplastic left heart syndrome even though both ventricles are functioning normally. These defects are common in DiGeorge syndrome and include interrupted aortic arch and LVOT obstruction (IAA/LVOTO); aortic atresia-severe stenosis with ventricular septal defect (AA/VSD); and aortic atresia with interrupted aortic arch and aortopulmonary window. This procedure allows the surgeon to keep the left ventricle connected to the systemic circulation while using the pulmonary valve as its outflow valve, by connecting them through the ventricular septal defect. The Yasui procedure includes a modified Damus–Kaye–Stansel procedure to connect the aortic and pulmonary roots, allowing the coronary arteries to remain perfused. It was first described in 1987.

References

  1. 1 2 3 4 5 6 7 Wilson W, Osten M, Benson L, Horlick E (January 2014). "Evolving trends in interventional cardiology: endovascular options for congenital disease in adults". The Canadian Journal of Cardiology. 30 (1): 75–86. doi: 10.1016/j.cjca.2013.11.006 . PMID   24365192.
  2. ↑ "Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction". NICE. 23 January 2013. Retrieved 25 March 2019.
  3. ↑ Jalal Z, Thambo JB, Boudjemline Y (November 2014). "The future of transcatheter pulmonary valvulation". Archives of Cardiovascular Diseases. 107 (11): 635–42. doi:10.1016/j.acvd.2014.07.046. PMID   25241221.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Ansari MM, Cardoso R, Garcia D, Sandhu S, Horlick E, Brinster D, et al. (November 2015). "Percutaneous Pulmonary Valve Implantation: Present Status and Evolving Future". Journal of the American College of Cardiology. 66 (20): 2246–2255. doi:10.1016/j.jacc.2015.09.055. PMID   26564602.
  5. 1 2 3 Virk SA, Liou K, Chandrakumar D, Gupta S, Cao C (December 2015). "Percutaneous pulmonary valve implantation: A systematic review of clinical outcomes". International Journal of Cardiology. 201: 487–9. doi:10.1016/j.ijcard.2015.08.119. PMID   26313872.
  6. 1 2 3 4 5 6 7 8 9 Qureshi AM, Prieto LR (June 2015). "Percutaneous pulmonary valve placement". Texas Heart Institute Journal. 42 (3): 195–201. doi:10.14503/THIJ-14-4276. PMC   4473610 . PMID   26175629.
  7. ↑ Bonhoeffer P, Boudjemline Y, Saliba Z, Merckx J, Aggoun Y, Bonnet D, et al. (October 2000). "Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction". Lancet. 356 (9239): 1403–5. doi:10.1016/S0140-6736(00)02844-0. PMID   11052583. S2CID   38642691.
  8. ↑ "FDA Approves Edwards Sapien 3 Transcatheter Heart Valve". Cardiac Interventions Today. Retrieved 21 December 2020.
  9. ↑ de Torres-Alba F, Kaleschke G, Baumgartner H (October 2018). "Impact of Percutaneous Pulmonary Valve Implantation on the Timing of Reintervention for Right Ventricular Outflow Tract Dysfunction". Revista Espanola de Cardiologia. 71 (10): 838–846. doi:10.1016/j.rec.2018.05.001. PMID   29859895. S2CID   44167038.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.